Track record · closed signal

Abbott Laboratories (ABT) — closed signal from April 27, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 26, 2026 — +11.8% at the close.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted

$87.74 – $92.18Entry zone — fair-value band

$92.16Published — price the day we called it

$102.49Target — the price the thesis aimed for

$104.18Peak — highest point inside the window, not a realized return

$103.06Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 88 days.

At window close

+11.8%

realized, from the publication price to the last close inside the window

Peak gain

+13%

peak, from the publication price — not a realized return

S&P 500, same window

+3.6%

SPY over the identical days, dividend-adjusted

Window close

$103.06

last close inside the window, ended July 26, 2026

Peak price

$104.18

peak on July 24, 2026 — not a realized return

Days to target

The thesis — published April 27, 2026

Predicted growth

+12%

over the measurement window

Target price

$102.49

the price the thesis aimed for

Entry zone

$87.74 – $92.18

the fair-value band we waited for

Price at publication

$92.16

published April 27, 2026

Confidence

65%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Abbott is seen as a defensive, contrarian idea after the stock fell sharply. New cardiac-device results are promising for future products, but a recent downgrade and weaker profit expectations make the outlook fragile. Because many investors recently sold, a bounce is possible if selling calms, but the stock needs clearer signs that selling has stopped before conviction improves.

Primary drivers

Broad healthcare mix provides defensive exposure across products
Positive cardiac-device results support future product strength
Recent heavy selling could allow a bounce if selling calms
Analyst downgrade and weaker profit views limit confidence
mdRationale_simple
mdReasoning_simple

How it played out

ABT: target reached in 88 days

Lyra published a contrarian rebound thesis at $92.16 and expected 12% growth. The thesis pointed to Abbott's broad healthcare mix, promising cardiac-device results, and the possibility that heavy selling could calm. It also noted an analyst downgrade and weaker profit expectations, which limited confidence.

The shares reached the $102.49 target in 88 days. They peaked at $104.18 on July 24, a 13% gain, then ended the window at $103.06. The peak and closing price were both above the target. The thesis played out.

What happened during the window

On May 27, Abbott said it had secured CE Mark for its Libre Duo glucose-ketone sensing systems. On July 16, Abbott reported second-quarter sales growth of 13.0% and raised its full-year adjusted earnings guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABT signals